|
|
|
| Clinical Efficacy of Sulodexide Combined with Epalrestat in the Treatment of Type 2 Diabetes Mellitus Complicated with Diabetic Peripheral Neuropathy |
| WU Changhao |
| Department of Endocrine,China Rongtong Medical Health Group Yichang No.154 Hospital,Xinyang Henan 464000 |
|
|
|
|
Abstract 【Objective】To investigate the clinical efficacy of Sulodexide combined with epalrestat in the treatment of type 2 diabetesmellitus (T2DM) patients with diabetic peripheral neuropathy (DPN).【Methods】A total of 95 T2DM patients with DPN treated in our hospital from February 2020 to March 2023 were selected and divided into control group (receiving epalrestat treatment, n=46) and observation group (receiving Sulodexide treatment on the basis of control group treatment, n=49) according to different treatment methods. The clinical efficacy, clinical score, nerve conduction velocity, glycated hemoglobin(HbA1c), fasting blood glucose (FPG), serological indexes and incidence of adverse reactions were compared between the two groups.【Results】The total effective rate of the observation group was higher than that of the control group (P<0.05). After treatment, the pain, paresthesia, burning sensation, numbness scores and serum malondialdehyde (MDA) and endothelin-1 (ET-1) levels in both groups were lower than before treatment (P<0.05), and the pain, paresthesia, burning sensation, numbness scores and serum MDA and ET-1 levels in the observation group were lower than those in the control group (P<0.05). After treatment, the sensory conduction velocity (SNCV), motor conduction velocity (MNCV) and serum nitric oxide (NO) levels of the median nerve and common peroneal nerve in both groups were higher than before treatment (P<0.05), and the levels of SNCV, MNCV and NO in the median nerve and common peroneal nerve in the observation group were higher than those in the control group (P<0.05). After treatment, the HbA1c and FPG of both groups were lower than before treatment (P<0.05), and the HbA1c and FPG of observation group were lower than those of control group (P<0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P>0.05).【Conclusion】Sulodexide combined with epalrestat is effective in the treatment of T2DM patients with DPN, and can improve blood glucose control, clinical symptoms, oxidative stress index, vascular endothelial function index, nerve conduction velocity, and is safe and reliable.
|
|
Received: 04 June 2024
|
|
|
|
|
|
[1] 陈丽娜,苏青,张洪梅. 2型糖尿病患者周围神经病变与血清肿瘤标志物的关系研究[J].中华内分泌代谢杂志,2023,39(10):852-857.
[2] 丁蕊,冯皓月,颜大为,等. 血管新生在糖尿病周围神经病变中的研究进展[J].中华糖尿病杂志,2023,15(11):1167-1171.
[3] TINAJERO M G, MALIK V S. An update on the epidemiology of type 2 diabetes: a global perspective[J].Endocrinol Metab Clin North Am,2021,50(3):337-355.
[4] 代肖,许奕航,马利双,等. 达格列净与二甲双胍对每日两次预混胰岛素注射治疗血糖未达标2型糖尿病患者血糖控制的影响[J].中国医药,2023,18(11):1660-1664.
[5] 黄辛炜,林夏鸿. 非编码RNA在糖尿病周围神经病变发病机制中的作用[J].中华糖尿病杂志,2022,14(8):860-864.
[6] 庄海容,吴子东,陈雪红,等. 舒洛地特对大鼠糖尿病视网膜病变的修复及MAPK通路的调节作用[J].解剖学报,2023,54(4):392-399.
[7] 王超群,邹俊杰,汤玮,等. 静脉滴注联合不同口服药物治疗糖尿病周围神经病变的疗效及安全性[J].药学服务与研究,2015,15(2):119-122.
[8] 郭威,石小霞,刘丹,等. 维生素D2注射液联合硫辛酸注射液治疗2型糖尿病合并糖尿病周围神经病变患者的临床研究[J].中国临床药理学杂志,2022,38(19):2263-2267.
[9] 石桩,杜兰,澈力格尔,等. 糖尿病周围神经病变相关机制研究进展[J].足踝外科电子杂志,2021,8(1):53-56.
[10] 朱春梅,于瑞华,郑娜娜,等. 血脂康胶囊联合依帕司他对糖尿病周围神经病变的疗效及安全性研究[J].实用临床医药杂志,2023,27(20):127-130.
[11] 陈丽娜,苏青,张洪梅. 2型糖尿病患者周围神经病变与血清肿瘤标志物的关系研究[J].中华内分泌代谢杂志,2023,39(10):852-857.
[12] 宋荷花,魏在荣. 糖尿病的周围神经病变:研究与治疗[J].中国组织工程研究,2023,27(8):1278-1285.
[13] 张鹏飞,布琼星,衡艳艳,等. 胰激肽原酶联合舒洛地特治疗糖尿病肾病的效果及对肾功能和血脂的影响[J].临床误诊误治,2022,35(9):31-34.
[14] 周琳,刘伟,韩硕,等. 舒洛地特联合羟苯磺酸钙治疗高血压合并2型糖尿病肾病患者的效果及对碳水化合物反应元件结合蛋白和分泌型卷曲相关蛋白5水平的影响[J].中华高血压杂志,2022,30(1):73-77.
[15] 李合,王人卫,侯希贺,等. 12周快步走对绝经后原发性高血压患者血清ET-1、NO及eNOS的影响[J].北京体育大学学报,2018,41(5):64-70.
[16] 康建芳,孙昊,冯军. 康柏西普联合依帕司他治疗糖尿病视网膜病变患者的临床研究[J].中国临床药理学杂志,2021,37(9):1048-1051. |
|
|
|
2024, Vol. 41 
